What’s the current market cap for Hinge Health stock?

Hinge Health (HNGE) has a market cap of $5.2bn as of June 17, 2026.

What is the P/E ratio for Hinge Health stock?

The price to earnings (P/E) ratio for Hinge Health (HNGE) stock is 0 as of June 17, 2026.

Does Hinge Health stock pay dividends?

No, Hinge Health (HNGE) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Hinge Health dividend payment date?

Hinge Health (HNGE) stock does not pay dividends to its shareholders.

What is the beta indicator for Hinge Health?

Hinge Health (HNGE) does not currently have a Beta indicator.

Buy Hinge Health stock | $HNGE Share Price

13:30

15:10

16:45

18:25

20:00

About Hinge Health

Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address chronic musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients.

Ticker

$HNGE

Sector

Health

Primary listing

NYSE

Employees

1,437

Headquarters

San Francisco, United States

Website

www.hingehealth.com

Hinge Health Metrics

BasicAdvanced

$5.2bn

-$7.27

What the Analysts think about Hinge Health

Analyst ratings (Buy, Hold, Sell) for Hinge Health stock.

Bulls say / Bears say

Hinge Health generated $182 million in revenue in Q1 2026, a 47% year-over-year increase that outpaced analyst expectations, reflecting strong demand for its AI-driven care platform (SEC Filing)

The company raised its full-year 2026 revenue guidance to $798 million–$804 million (36% growth midpoint), up from prior guidance of $732 million–$742 million, signaling confidence in sustained commercial momentum (Motley Fool)

In April 2026, Hinge Health launched a comprehensive Migraine Care Program adopted by over two million covered lives, expanding its service offerings beyond musculoskeletal care and addressing a leading cause of disability in under-50s (Hinge Health Press Release)

Despite non-GAAP profitability, Hinge Health reported a GAAP loss from operations of $546.4 million for full-year 2025, underscoring significant stock-based compensation and other adjustments that may dampen investor sentiment if those costs persist (BusinessWire)

Revenue contribution from the Hinge Select provider network remains unproven, with meaningful impact not expected until after 2026, posing execution risk for this new initiative (Motley Fool)

In its 2025 Form 10-K, Hinge Health identifies potential liabilities from patient data privacy breaches and evolving telehealth regulations, any of which could lead to material penalties and reputational damage (SEC Filing)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Hinge Health Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Hinge Health Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HNGE

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Hinge Health generated $182 million in revenue in Q1 2026, a 47% year-over-year increase that outpaced analyst expectations, reflecting strong demand for its AI-driven care platform (SEC Filing)

Revenue contribution from the Hinge Select provider network remains unproven, with meaningful impact not expected until after 2026, posing execution risk for this new initiative (Motley Fool)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.